Abivax SA
ABVX82.300USD
-1.010-1.21%
收盘 09/19, 16:00（美东）报价延迟15分钟
0.00总市值
--市盈率 TTM
关于 Abivax SA 公司
Abivax SA 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒化合物和治疗性疫苗，以对抗严重和危及生命的传染病。ABIVAX 利用 RNA-蛋白质相互作用干扰和细胞毒性 TH1 细胞扩增来产生疗法，帮助患者清除 HIV、HBV 和 HPV 等病毒。该公司的产品线包括 ABX 203，这是从古巴遗传工程和生物技术中心 (CIGB) 获得的治疗性疫苗候选药物，适用于患有慢性乙型肝炎的患者；以及 ABX196，治疗性疫苗的佐剂等。
公司简介
公司代码ABVX
公司名称Abivax SA
上市日期Jun 26, 2015
CEOMr. Marc De Garidel
员工数量- -
证券类型Ordinary Share
年结日- -
公司地址7-11 Boulevard Haussmann
城市PARIS
上市交易所Euronext Paris
国家France
邮编75009
电话33153830963
网址https://www.abivax.com/
公司代码ABVX
上市日期Jun 26, 2015
CEOMr. Marc De Garidel
公司高管
名称
名称/职务
职务
持股
持股变动
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mary Mantock
Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Mr. Patrick Malloy
Mr. Patrick Malloy
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月3日 周三
更新时间: 9月3日 周三
持股股东
股东类型
持股股东
持股股东
占比
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
其他
77.69%
持股股东
持股股东
占比
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
其他
77.69%
股东类型
持股股东
占比
Hedge Fund
24.85%
Investment Advisor
11.49%
Investment Advisor/Hedge Fund
5.43%
Venture Capital
1.95%
Research Firm
0.89%
其他
55.39%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
74
31.84M
43.27%
-317.11K
2025Q1
74
31.82M
50.18%
-39.44K
2024Q4
67
29.91M
47.53%
+1.67M
2024Q3
53
27.43M
43.59%
-1.47M
2024Q2
50
28.12M
44.69%
-980.96K
2024Q1
45
23.37M
37.15%
+1.78M
2023Q4
32
21.64M
34.39%
+20.54M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
TCG Crossover Management, LLC
6.06M
9.55%
--
--
Mar 31, 2025
Deep Track Capital LP
3.58M
5.64%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
2.21M
3.48%
+696.63K
+46.03%
Mar 31, 2025
Cormorant Asset Management, LP
2.13M
3.36%
--
--
Mar 31, 2025
Caligan Partners, LP
1.27M
2%
+516.95K
+68.73%
Mar 31, 2025
Nantahala Capital Management, LLC
1.48M
2.34%
+46.95K
+3.27%
Mar 31, 2025
Franklin Advisers, Inc.
1.37M
2.16%
-95.01K
-6.48%
Mar 31, 2025
VR Adviser, LLC
1.35M
2.12%
--
--
Mar 31, 2025
Great Point Partners, LLC
1.64M
2.58%
-10.41K
-0.63%
Mar 31, 2025
Octagon Capital Advisors LP
1.23M
1.94%
+1.23M
--
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
